Condition: Myeloproliferative Neoplasm · Sponsor: University Health Network, Toronto
The purpose of this research study is to look at how safe and useful a drug called azacitidine in combination with a drug called venetoclax, is in people with accelerated or blast phase BRC-ABL negative myeloproliferative neoplasms.
This description comes directly from the study's public registry record.
Vikas Gupta, M.D. · 416-946-2885 · vikas.gupta@uhn.ca
Always discuss trial participation with your own doctor first.
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05074355